These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 34352610)

  • 1. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
    Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
    Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.
    Pötter-Nerger M; Dutke J; Lezius S; Buhmann C; Schulz R; Gerloff C; Kuhle J; Choe CU
    J Neural Transm (Vienna); 2022 Mar; 129(3):295-300. PubMed ID: 35072765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study.
    Choe CU; Petersen E; Lezius S; Cheng B; Schulz R; Buhmann C; Pötter-Nerger M; Daum G; Blankenberg S; Gerloff C; Schwedhelm E; Zeller T
    Parkinsonism Relat Disord; 2021 Apr; 85():5-10. PubMed ID: 33636481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease.
    Lin YS; Lee WJ; Wang SJ; Fuh JL
    Sci Rep; 2018 Nov; 8(1):17368. PubMed ID: 30478269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease.
    Sleeman I; Lawson RA; Yarnall AJ; Duncan GW; Johnston F; Khoo TK; Burn DJ
    J Parkinsons Dis; 2019; 9(2):351-359. PubMed ID: 30909247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.
    Ou R; Liu K; Lin J; Yang T; Xiao Y; Wei Q; Hou Y; Li C; Zhang L; Jiang Z; Zhao B; Chen X; Song W; Wu Y; Shang H
    J Neurol; 2024 Apr; 271(4):1837-1843. PubMed ID: 38063869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
    Uyar M; Lezius S; Buhmann C; Pötter-Nerger M; Schulz R; Meier S; Gerloff C; Kuhle J; Choe CU
    Mov Disord; 2022 Jun; 37(6):1299-1304. PubMed ID: 35384057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood neurofilament light chain in Parkinson's disease.
    Buhmann C; Magnus T; Choe CU
    J Neural Transm (Vienna); 2023 Jun; 130(6):755-762. PubMed ID: 37067597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson's disease patients.
    Peng Y; Zhu L; Bai Q; Wang L; Li Q
    Acta Neurol Belg; 2024 Jun; 124(3):879-885. PubMed ID: 38286872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
    Huang Y; Huang C; Zhang Q; Shen T; Sun J
    BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.